Inactive Instrument

Jaguar Health Inc Share Price Nasdaq

Equities

US47010C3007

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 15.11M 1.26B Sales 2025 * 22.66M 1.89B Capitalization 70.46M 5.88B
Net income 2024 * -26M -2.17B Net income 2025 * -21M -1.75B EV / Sales 2024 * 4.66 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.11 x
P/E ratio 2024 *
-2.83 x
P/E ratio 2025 *
-3.64 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.78%
More Fundamentals * Assessed data
Dynamic Chart
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q1 Revenue $2.4M, vs. Street Est of $3M MT
Transcript : Jaguar Health, Inc., Q1 2024 Earnings Call, May 14, 2024
Jaguar Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment MT
Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration CI
Venture Life renews revolving credit facility with Santander and HSBC AN
Jaguar Health, Inc. Appoints Catherine Miller Collis to the Role of Senior Vice President of Growth Strategy CI
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected MT
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes MT
Top Premarket Gainers MT
Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International CI
Transcript : Jaguar Health, Inc., Q4 2023 Earnings Call, Apr 01, 2024
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study MT
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs CI
More news
Managers TitleAgeSince
Founder 65 06/13/06
Director of Finance/CFO 60 01/19/01
Chief Tech/Sci/R&D Officer 60 01/17/01
Members of the board TitleAgeSince
Founder 65 06/13/06
Chairman 80 01/14/01
Director/Board Member 71 01/16/01
More insiders
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW